Industry incumbents may be weighed down by legacy mindsets and infrastructure, but EQRx will need to be very light on its feet if it hopes to outrun them. This is a16z's sweet spot: battle-hardened entrepreneurs with a bold vision for how to use technology to transform an industry and build a new world. I am thrilled to announce that a16z, along with ARCH and GV, is co-leading the Series A investment in EQRx, joined by an incredible group of investors including Casdin Capital, Section 32, Nextech, and Arboretum Ventures. As a board member, I'm honored to support EQRX's commitment to making innovative medicines at dramatically lower prices for the benefit of people, the system and society. Most companies have a mission statement. EQRx has a rallying cry: "Remake medicine." Because it's about time.